Summary
The interaction of locally perfused cholecystokinin-8 (sulphated) with systemically administered apomorphine was studied on the release of dopamine and its metabolites using microdialysis in the neostriatum of the halothane-anaesthetized male rat. Dialysate levels of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid were assayed by high performance liquid chromatography in combination with electrochemical detection. Perfusion with cholecystokinin-8 (100 μM but not 1 μM or 10 nM) increased the dialysate levels of dopamine without affecting those of DOPAC or HVA. At low concentrations (1 μM and 10 nM but not 1 nM), cholecystokinin-8 counteracted the inhibitory effect of apomorphine (0.05 mg/kg, s. c.) on dopamine release. This counteraction was antagonized by perfusion with the cholecystokinin-8 antagonist proglumide (3 μM). At this concentration, proglumide perfused alone was without effect on basal or apomorphine-reduced levels of dopamine. The results indicate a facilitatory effect of cholecystokinin-8 on dopamine release in rat neostriatum only at high concentrations. At lower concentrations, cholecystokinin-8 appears to modulate dopamine release by an inhibitory effect on dopamine autoreceptors possibly involving an intramembrane interaction between presynaptic cholecystokinin-8 receptors and dopamine autoreceptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agnati LF, Fuxe K (1983) Subcortical limbic 3H-N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro. Biosci Rep 3:1101–1105
Agnati LF, Celani MF, Fuxe K (1983) Cholecystokinin peptides in vitro modulate the characteristics of striatal [3H]N-propylnorapomorphine binding sites. Acta Physiol Scand 118:79–81
Bean AJ, During MJ, Roth RH (1989) Stimulation-induced release of coexistent transmitters in the prefrontal cortex: an in vivo microdialysis study of dopamine and neurotensin release. J Neurochem 53:655–657
Bunney BS, Chiodo LA, Freeman AS (1985) Further studies on the specificity of proglumide as a selective cholecystokinin antagonist in the central nervous system. Ann NY Acad Sci USA 448:345–351
Carlson A (1975) Receptor mediated control of dopamine metabolism. In: Usdin E, Bunney WE (eds) Catecholamines: Basic and Clinical Frontiers. Dekker, New York, pp 49–65
Chiodo LA, Bunney BS (1983) Proglumide: selective antagonism of excitatory effects of cholecystokinin in the central nervous system. Science 219:1449–1451
Commisong JW (1985) Monoamine metabolites; their relationship and lack of relationship to monoamine neuronal activity. Biochem Pharmacol 34:1127–1131
Di Chiara G, Proceddu ML, Vargin L, Stefanini E, Gessa GL (1976) Evidence for dopamine receptors mediating sedation in the mouse. Nature 264:564–567
von Euler G, Fuxe K, Tanganelli S, Finnman U-B, Eneroth P (1990) Changes in pituitary-adrenal activity affect the binding properties of striatal dopamine D-2 receptors but not their modulation by neurotensin and cholecystokinin-8. Neurochem Int 16:275–280
Fuxe K, Andersson K, Locatelli V, Agnati LF, Hokfelt T, Skirboll L, Mutt V (1980) Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. Eur J Pharmacol 67:329–331
Fuxe K, Agnati LF, Benfenati F, Cimino M, Algeri S, Hökfelt T, Mutt V (1981) Modulation of cholecystokinins of 3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiol Scand 113:567–569
Fuxe K, Agnati LF, Vanderhaeghen J-J, Tatemoto K, Andersson K, Eneroth P, Harfstrand A, von Euler G, Toni R, Goldstein M, Mutt V (1985) Cholecystokinin neuron systems and their interactions with the presynaptic features of the dopamine neuron systems: A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58. Ann NY Acad Sci USA 448:231–254
Hommer D, Skirboll L (1983) Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons. Eur J Pharmacol 91:151–152
Hökfelt T, Rehfelt JF, Skirboll L, Ivemark B, Goldstein M, Markey K (1980) Evidence for coexistence of dopamine and CCK in mesolimbic neurons. Nature 285:476–478
Imperato A, Di Chiara G (1988) Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur J Pharmacol 156:385–393
Lehmann J, Briley M, Langer SZ (1983) Characterization of dopamine autoreceptors and 3H-spiperone binding sites in vitro with classical and novel dopamine receptor agonists. Eur J Pharmacol 88:11–26
Markstein R, Hökfelt T (1984) Effects of cholecystokinin octapeptide on dopamine release from slices of cat caudate nucleus. J Neurosci 4:570–575
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
Roth R (1979) Dopamine autoreceptors: pharmacology, function and comparison with post-synaptic dopamine receptors. Commun Psychopharmacol 3:429–445
Ruggeri M, Ungerstedt U, Agnati LF, Mutt V, Harfstrand A, Fuxe K (1987) Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracisternal dialysis in the anaesthetized rat. Neurochem Int 10:509–520
Skirboll LR, Grace AA, Bunney BS (1979) Dopamine auto- and post-synaptic receptors: electrophysiological evidence for a differential sensitivity to dopamine agonists. Science 206:80–82
Starke K, Göthert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864–989
Tanganelli S, von Euler G, Fuxe K, Agnati LF, Ungerstedt U (1989) Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum. Brain Res 502:319–324
Ungerstedt U (1984) Measurement of neurotransmitter release by intracranial dialysis. In: Marsden CD (ed) Measurement of neurotransmitter release in vitro. Wiley, New York, pp 81–105
Voigt MM, Wang RY (1984) In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin. Brain Res 296:189–193
Wang RY (1988) Co-localization of dopamine and cholecystokinin: functional significance. Prog. Catecholamine Res., Part B, Central Aspects. Liss, New York, pp 217–224
Watkins LR, Kinscheck IB, Mayer DJ (1984) Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 224:395–396
Watkins LR, Kinscheck IB, Mayer DJ (1985) Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res 327:169–180
Zetterström T, Ungerstedt U (1984) Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis. Eur J Pharmacol 97:29–36
Author information
Authors and Affiliations
Additional information
Send offprint requests to K. Fuxe at the above address
Rights and permissions
About this article
Cite this article
Tanganelli, S., Fuxe, K., von Euler, G. et al. Involvement of cholecystokinin receptors in the control of striatal dopamine autoreceptors. Naunyn-Schmiedeberg's Arch Pharmacol 342, 300–304 (1990). https://doi.org/10.1007/BF00169441
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00169441